Table 2

Baseline characteristics of patients in the intervention arm

CharacteristicREACH-HF n=107 (%)Qualitative interview sample n=19 (%)
Age (years), mean (SD)69.7 (10.9)68.5 (9.8)
Female sex26 (24)7 (37)
Body Mass Index BMI (kg/m2); mean (SD)29.5 (6.6)31.5 (7.4)
Main activity
 Retired81 (76)15 (79)
 In employment or self-employment18 (17)2 (11)
 Unemployed5 (5)1 (5)
 Other3 (3)1 (5)
Ethnic origin
 White100 (93)19 (100)
 Other (Black, Asian, other)7 (7)0 (0)
NYHA status
 Class I24 (22)0 (0)
 Class II63 (59)13 (68)
 Class III20 (19)6 (32)
Ischaemic aetiology of HF48 (45)9 (47)
Time since diagnosis of HF (years); mean (SD)3.6 (4.2)3.8 (3.9)
 <135 (33)6 (32)
 1–218 (17)1 (5)
 2–528 (26)7 (37)
 5–1014 (13)3 (16)
 >1012 (11)2 (11)
NTerminal-pro-BNP level (pg/mL); mean (SD)1460 (1928)1321 (1123)
Current smoker6 (6)1 (5)
Comorbidities (past or present)
 Diabetes mellitus26 (24)5 (26)
 Myocardial infarction29 (27)7 (37)
 Hypertension45 (42)9 (47)
 Chronic renal impairment14 (13)3 (16)
 Arthritis (osteoarthritis or rheumatoid)45 (42)11 (58)
 Atrial fibrillation or atrial flutter48 (45)9 (47)
 COPD9 (8)2 (11)
 Depression27 (25)7 (37)
Number of comorbidities
 063 (59)9 (47)
 132 (30)7 (37)
 27 (7)1 (5)
 3 or more5 (5)2 (11)
Baseline use of drugs
 Beta-blocker90 (84)18 (5)
 Angiotensin II receptor antagonist31 (29)8 (42)
 ACE inhibitor68 (64)10 (53)
 Baseline use of devices
 Implantable cardiverter defibillator (ICD)10 (9)3 (16)
 Cardiac Synchronization Therapy (CRT)10 (9)1 (5)
 Combined CRT/ICD5 (5)2 (11)
 Pacemaker11 (10)1 (5)
Location
 Cornwall30 (28)7 (37)
 Gwent23 (22)3 (16)
 Birmingham27 (25)4 (21)
 York27 (25)5 (26)
Caregiver present at randomisation53 (50)13 (68)
  • COPD, chronic obstructive pulmonary disease; HF, heart failure; NYHA, New York Heart Association.